NDA 009386 · Waylis Therap
Myleran
Busulfan · Oral · Alkylating Drug
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Dec 24, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1954
Jun 26, 1954
Approved uses
1
Original approval plus efficacy supplements
Registered trials
684
99 Phase 3, 72 recruiting
FAERS reports
15,920
15,144 serious, 4,660 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING MYLERAN is a potent drug. It should not be used unless a diagnosis of chronic myelogenous leukemia has been adequately established and the responsible physician is knowledgeable in assessing response to chemotherapy. MYLERAN can induce severe bone marrow hypoplasia. Reduce or discontinue the dosage immediately at the first sign of any unusual depression of bone marrow function as reflected by an abnormal decrease in any of the formed elements of the blood. A bone marrow examination should be performed if the bone marrow status is uncertain. SEE WARNINGS FOR INFORMATION REGARDING BUSULFAN-INDUCED LEUKEMOGENESIS IN HUMANS.
What it is approved for
From the label in effect Jan 8, 2025.
INDICATIONS AND USAGE MYLERAN (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 26, 1954 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- MYLERAN · BUSULFAN 2MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Busulfan" as an intervention, any sponsor and status, largest first.
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
- Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid LeukemiaPivotal-lookingStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00004128 · 2,000 participants (planned) · Start Sep 1999 · Primary completion Jan 2008
Drug: aldesleukin; filgrastim and 5 more · For: Leukemia
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesPivotal-lookingCompleted
The University of New South WalesAcademic, hospital or other
NCT00454480 · 2,000 participants (planned) · Start Aug 2006 · Primary completion Aug 2012
Drug: alemtuzumab; arsenic trioxide and 9 more · For: Leukemia; Myelodysplastic Syndromes
Sites: Basingstoke, United Kingdom; Bath, United Kingdom; Birmingham, United Kingdom · 96 sites in all
- Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01949129 · 1,800 participants (planned) · Start Apr 2013 · Primary completion Jun 1, 2030
Drug: VP16; Thiotepa and 6 more · For: Acute Lymphoblastic Leukaemia
Sites: Buenos Aires, Argentina; La Plata, Argentina; Melbourne, Australia · 119 sites in all
- Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous LeukemiaPivotal-lookingStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00002549 · 1,520 participants (planned) · Start Nov 1993
Drug: filgrastim; busulfan and 7 more · For: Leukemia
Sites: Innsbruck, Austria; Antwerp, Belgium; Bruges, Belgium · 75 sites in all
- Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's SarcomaPivotal-lookingStatus unknown
University of LeicesterAcademic, hospital or other
NCT00020566 · 1,200 participants (planned) · Start Feb 2001 · Primary completion Dec 2011
Drug: dactinomycin; busulfan and 5 more · For: Sarcoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 103 sites in all
- Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous LeukemiaPivotal-lookingStatus unknown
III. Medizinische Klinik MannheimAcademic, hospital or other
NCT00025402 · 1,000 participants (planned) · Start Jul 1997
Drug: filgrastim; recombinant interferon alfa and 6 more · For: Leukemia
Sites: Brno, Czechia; Aachen, Germany; Aalen, Germany · 188 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,098
- product use in unapproved indication1,727
- mucosal inflammation1,121
- drug ineffective1,088
- graft versus host disease922
- venoocclusive liver disease888
- febrile neutropenia886
- cytomegalovirus infection881
- acute graft versus host disease832
- pyrexia827
- chronic graft versus host disease645
- cytomegalovirus infection reactivation619
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 112 |
| 2005 | 139 |
| 2006 | 83 |
| 2007 | 101 |
| 2008 | 224 |
| 2009 | 154 |
| 2010 | 212 |
| 2011 | 603 |
| 2012 | 441 |
| 2013 | 291 |
| 2014 | 504 |
| 2015 | 357 |
| 2016 | 446 |
| 2017 | 716 |
| 2018 | 1,123 |
| 2019 | 1,410 |
| 2020 | 1,532 |
| 2021 | 1,397 |
| 2022 | 1,176 |
| 2023 | 1,067 |
| 2024 | 1,437 |
| 2025 | 1,475 |
| 2026 | 919 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Myleran (Busulfan)
2024 spending
$177K
Beneficiaries
n/a
16 claims
Per beneficiary
n/a
$278.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $92,104 |
| 2024 | $176,645 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Exagamglogene Autotemcel for Severe Sickle Cell Disease.
Frangoul H, Locatelli F, Sharma A, et al. · N Engl J Med 2024 · Multicenter Study, Clinical Trial, Phase III
- Lentiviral Gene Therapy for Artemis-Deficient SCID.
Cowan MJ, Yu J, Facchino J, et al. · N Engl J Med 2022 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Prime Editing for p47phox-Deficient Chronic Granulomatous Disease.
Gori JL, Haddad E, Frangoul H, et al. · N Engl J Med 2026 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia.
Locatelli F, Thompson AA, Kwiatkowski JL, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Multicenter Study
- Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW, Trenschel R, Stelljes M, et al. · Lancet Haematol 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
- [Ranimustine].
Masaoka T · Gan To Kagaku Ryoho 1990 · Clinical Trial, Comparative Study
Sponsor: Waylis Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.